Antineoplastic Agents, Hormonal

"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Descriptor ID	D018931
MeSH Number(s)	D27.505.954.248.169
Concept/Terms	Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Hormonal Agents, Antineoplastic Hormonal Antineoplastic Agents Hormonal Antineoplastics Antineoplastic Hormonal Drugs Drugs, Antineoplastic Hormonal Hormonal Drugs, Antineoplastic Hormonal Antineoplastic Drugs Antineoplastics, Hormonal Antineoplastic Hormonal Agents Agents, Antineoplastic Hormonal Antineoplastic Drugs, Hormonal

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Hormonal [D27.505.954.248.169]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Hormonal".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.

Bar chart showing 32 publications over 18 distinct years, with a maximum of 5 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	2	3
2000	0	1	1
2003	0	1	1
2004	0	1	1
2005	1	1	2
2006	0	1	1
2009	1	0	1
2010	1	0	1
2012	2	0	2
2013	1	3	4
2014	1	0	1
2015	3	2	5
2016	1	0	1
2018	1	2	3
2019	1	0	1
2020	1	0	1
2023	0	2	2
2024	0	1	1

Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.

Bhardwaj PV, Abdou Y. Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies. J Clin Oncol. 2024 Dec; 42(34):4012-4017.

View in: PubMed
Schwartz GN, Kaufman PA, Giridhar KV, Marotti JD, Chamberlin MD, Arrick BA, Makari-Judson G, Goetz MP, Soucy SM, Kolling F, Demidenko E, Miller TW. Alternating 17?-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. Clin Cancer Res. 2023 08 01; 29(15):2767-2773.

View in: PubMed
Khor CC, Winter S, Sutiman N, M?rdter TE, Chen S, Lim JSL, Li Z, Li J, Sim KS, Ganchev B, Eccles D, Eccles B, Tapper W, Zgheib NK, Tfayli A, Ng RCH, Yap YS, Lim E, Wong M, Wong NS, Ang PCS, Dent R, Tremmel R, Klein K, Schaeffeler E, Zhou Y, Lauschke VM, Eichelbaum M, Schwab M, Brauch HB, Chowbay B, Schroth W. Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations. Clin Pharmacol Ther. 2023 03; 113(3):712-723.

View in: PubMed
Rizzo A, Merler S, Sorgentoni G, Oderda M, Mollica V, Gadaleta-Caldarola G, Santoni M, Massari F. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. Expert Opin Drug Metab Toxicol. 2021 Oct; 17(10):1237-1243.

View in: PubMed
Raghavan SS, Clark M, Louie CY, Jensen KC, Dietrich B, Beadle BM, El-Sawy T, Baik F, Kunder CA, Brown RA. Molecular profiling of a primary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid. J Cutan Pathol. 2020 Sep; 47(9):860-864.

View in: PubMed
Lee C, Check DK, Manace Brenman L, Kushi LH, Epstein MM, Neslund-Dudas C, Pawloski PA, Achacoso N, Laurent C, Fehrenbacher L, Habel LA. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.

View in: PubMed
Richards R, Keating E, Boucher JE. Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer. Clin J Oncol Nurs. 2019 08 01; 23(4):434-438.

View in: PubMed
Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate?Cancer: Meta-Analysis of Efficacy and Safety Outcomes. Clin Genitourin Cancer. 2019 10; 17(5):e871-e877.

View in: PubMed
Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, Scarpelli M, Montironi R, Massari F. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells. 2019 01 11; 8(1).

View in: PubMed
Karlsson E, Veenstra C, G?rsj? J, Nordenskj?ld B, Fornander T, St?l O. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer. J Cancer Res Clin Oncol. 2019 Mar; 145(3):599-607.

View in: PubMed

People

Explore

Similar Concepts

Top Journals